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Intermittent administration of parathyroid hormone
(iPTH) is used to treat osteoporosis because it im-
proves bone architecture and strength, but the
underlying cellular and molecular mechanisms are
unclear. Here, we show that iPTH increases the pro-
duction of Wnt10b by bone marrow CD8+ T cells and
induces these lymphocytes to activate canonical
Wnt signaling in preosteoblasts. Accordingly, in
responses to iPTH, T cell null mice display dimin-
ished Wnt signaling in preosteoblasts and blunted
osteoblastic commitment, proliferation, differentia-
tion, and life span, which result in decreased tra-
becular bone anabolism and no increase in strength.
Demonstrating the specific role of lymphocytic
Wnt10b, iPTH has no anabolic activity inmice lacking
T-cell-produced Wnt10b. Therefore, T-cell-mediated
activation of Wnt signaling in osteoblastic cells plays
a key permissive role in the mechanism by which
iPTH increases bone strength, suggesting that
T cell osteoblast crosstalk pathways may provide
pharmacological targets for bone anabolism.
INTRODUCTION
Sustained overproduction or in vivo continuous delivery of para-
thyroid hormone (PTH) is a cause of bone loss (Grey et al., 1996;
Potts, 1998). However, when injected daily, a regimen known as
intermittent PTH treatment, the hormone markedly stimulates
trabecular and cortical bone formation. Although this bone-form-
ing activity is antagonized, in part, by a stimulation of bone
resorption, the net effect of intermittent PTH treatment is an
improvement in bone microarchitecture and increased strengthCell M(Qin et al., 2004; Zaidi, 2007). As a result, intermittent treat-
ment with the 1–34 fragment of PTH is an FDA-approved treat-
ment modality for postmenopausal osteoporosis (Neer et al.,
2001).
PTH promotes bone formation by increasing the number of
osteoblasts (OBs) through multiple effects, including activation
of quiescent lining cells (Dobnig and Turner, 1995), increased
OB proliferation (Nishida et al., 1994; Pettway et al., 2007) and
differentiation (Nishida et al., 1994; Schmidt et al., 1995), and
attenuation of pre-OB and OB apoptosis (Almeida et al., 2005;
Bellido et al., 2003; Jilka et al., 1999). However, the specific
contribution of each of these effects to the overall anabolic
activity of PTH remains controversial.
PTH binds to the PTH/PTH-related protein (PTHrP) receptor
(PPR or PTH-1R), which is expressed on OBs, osteocytes, and
bone marrow (BM) stromal cells (SCs) (Calvi et al., 2001; Qin
et al., 2004). Ligand binding to PPR activates the cyclic AMP-
dependent protein kinase A and calcium-dependent protein
kinase C signaling pathways (Gensure et al., 2005; Jilka, 2007).
PTH signaling has been observed to intersectWnt pathways in
OBs. Activation of Wnt signaling induces OB proliferation (Kato
et al., 2002) and differentiation (Bodine and Komm, 2006), pre-
vents OB apoptosis (Almeida et al., 2005; Bodine et al., 2005),
and augments OB production of OPG (Glass et al., 2005),
a soluble decoy receptor for the osteoclastogenic cytokine
RANKL. Wnt proteins initiate a canonical signaling cascade by
binding to receptors of the Frizzled family together with corecep-
tors, members of the low-density lipoprotein receptor-related
protein (LRP) family, LRP5 and LRP6, which results in the stabi-
lization of cytosolic b-catenin. Interaction of b-catenin with tran-
scription factors of the lymphoid-enhancer-binding factor/T cell
factor family in the nucleus subsequently regulates the transcrip-
tion of Wnt target genes (Behrens et al., 1996). Wnt signaling
plays a critical role in bone formation, as inactivating mutations
of LRP5 cause osteoporosis in humans (Behrens et al., 1996)
and low bone mass in mice (Kato et al., 2002).etabolism 10, 229–240, September 2, 2009 ª2009 Elsevier Inc. 229
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Figure 1. Analysis of the Effects of iPTH Treatment in WTMice, TCRb/Mice, and TCRb/Mice Previously Subjected to Adoptive Transfer
of WT T Cells
(A) In vivo total body and femoral BMD measurements by DXA at 2 and 4 weeks of treatment.
(B) Femoral histology and ex vivo mCT analysis of femoral trabecular bone. Representative longitudinal histological sections stained by Goldner’s Trichrome stain,
cross-sectional mCT reconstructions, and trabecular bone volume (BV/TV) measured by bone histomorphometry and mCT are shown.230 Cell Metabolism 10, 229–240, September 2, 2009 ª2009 Elsevier Inc.
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PTH Anabolism and T-Cell-Produced Wnt10bPTH is a canonical Wnt signaling agonist that increases b-cat-
enin levels in osteoblastic cells (Kulkarni et al., 2005), an effect
that occurs through modulation of both the protein kinase A
and protein kinase C pathways (Tobimatsu et al., 2006). PTH,
once bound to PPR, is also capable of forming a complex with
LRP6 that results in LRP6 signaling and b-catenin activation
(Wan et al., 2008). Thus, PTH activates Wnt signaling in osteo-
blastic cells through both Wnt ligands’ dependent and inde-
pendent mechanisms. Moreover, PTH downregulates the pro-
duction of sclerostin, an osteocyte-derived Wnt-signaling
antagonist (Bellido et al., 2005), Dickkopf-1, a soluble LRP5-
and LRP6-signaling inhibitor (Kulkarni et al., 2005), and Sfrp-4,
a factor that binds Wnt proteins, thus antagonizing both canon-
ical and noncanonical Wnt signaling (Qin et al., 2003).
These reports suggest that Wnt signaling in cells of the osteo-
blastic lineage plays a role in PTH-induced anabolism. However,
uncertainty remains with regard to the relevance of canonical
Wnt signaling in the mode of action of PTH, as the silencing of
LRP5 does not abrogate trabecular bone anabolism (Iwaniec
et al., 2007; Sawakami et al., 2006). Furthermore, the identity
and source of Wnt ligands that activate Wnt signaling in
response to PTH treatment are not completely known.
Though SCs, OBs, and osteocytes represent themajor targets
of PTH in bone, accessory cells that express PPR may play
a contributory or permissive role. Among them are T lympho-
cytes, a lineage that responds to PTH (Geffner et al., 1995; Stoj-
ceva-Taneva et al., 1993), stimulates OB differentiation (Rifas
et al., 2003), and expresses Wnt10b (Hardiman et al., 1996;
Ouji et al., 2006), a Wnt ligand produced in the BM that inhibits
adipogenesis and stimulates osteoblastogenesis (Bennett et al.,
2005). We have reported that a continuous infusion of PTH fails
to induce bone resorption and cortical bone loss in mice lacking
T cells (Gao et al., 2008). This is because T cells increase the
capacity of SCs to support PTH-induced osteoclastogenesis
through CD40L, a surface molecule of activated T cells that
induces CD40 signaling in osteoblastic cells (Gao et al., 2008).
Although T cells in that study were found not to be required for
continuous PTH treatment to stimulate bone formation, little
information is available on whether T cells contribute to the
anabolic response to intermittent PTH.
In the present studies, we report that intermittent PTH treat-
ment increases the production of Wnt10b by BM CD8+ cells
and that deletion of T cells, or T-cell-expressed Wnt10b, results
in blunted trabecular bone anabolism.
RESULTS
T-Cell-Deficient Mice Exhibit a Blunted Anabolic
Response to iPTH
To determine whether T lymphocytes are required for intermit-
tent PTH to exert its effects on bone, 5-week-old wild-typeCell M(WT) and congenic TCRb/ mice, a strain completely devoid
of ab T cells, were injected daily with vehicle or 80 mg/kg of
hPTH 1–34 for 4 weeks, a treatment modality referred to here-
after as iPTH. To control for strain-dependent confounders, the
study included TCRb/ mice subjected to adoptive transfer of
WTT cells 1week before initiation of iPTH treatment, a procedure
that is followed by the engraftment and homeostatic expansion
of the donor T cells (Gao et al., 2007; Roggia et al., 2001). Dual
X-ray absorptiometry (DXA) was utilized to measure in vivo total
body and femoral bone mineral density (BMD). At baseline, WT
and TCRb/ mice had similar BMD values (Figure S1 available
online). Due to growth, BMD increased in all vehicle-treated
groups during the 4 weeks of the experiment (Figure 1A). In
WT and T-cell-reconstituted TCRb/ mice, iPTH induced a
55%–85% greater increase in the total body BMD and
a 70%–80% greater gain in femur BMD, as compared to
vehicle. Conversely, in T-cell-deficient TCRb/ mice, iPTH
augmented total body and femur BMD only 30% and 25%
more than vehicle, respectively.
Cancellous bone was analyzed by histology and microcom-
puted tomography (mCT), utilizing femurs that were harvested
at sacrifice. Histomorphometric measurements of trabecular
bone volume (BV/TV) revealed a less-pronounced anabolic
response to PTH in TCRb/ mice than in controls (Figure 1B).
mCT analysis showed that iPTH increased in all groups. However,
BV/TV was 46%–48% lower in iPTH-treated TCRb/ mice,
as compared to iPTH-treated WT and T-cell-reconstituted
controls. Parameters of trabecular structure (Figure 1C) were
also differentially affected in T-cell-deficient and T-cell-replete
mice, as trabecular number (Tb.N), trabecular separation
(Tb.Sp), connectivity density (Conn.D), and structure model
index (SMI) were more substantially improved in WT and recon-
stituted mice than in TCRb/ mice.
By contrast, mCT analysis of cortical bone showed that iPTH
induced similar increases in cortical thickness (Co.Th), cortical
volume (Co.V), and moment of inertia in all groups of mice
(Figure 1D), thus demonstrating that T cells specifically augment
the capacity of iPTH to improve architecture in trabecular bone.
Analysis of femoral structural properties by four-point bending
tests revealed that iPTH increased stiffness, failure load, and
maximum load in WT mice and T-cell-reconstituted TCRb/
mice, but not in T-cell-deficient TCRb/ mice (Figure 1E). As
structural properties reflect the strength of thewhole bone, these
findings demonstrate that lack of T cells blunts iPTH-induced
trabecular anabolism by a degree sufficient to hamper the
improvement in overall bone strength caused by iPTH.
Measurements of serum osteocalcin, a marker of bone forma-
tion, suggested that iPTH increased bone accretion in T-cell-
replete, but not in T-cell-deficient, mice (Figure 1F). Similarly,
assessment of the serum levels of C-terminal telopeptide of
collagen (CTx), a biochemical marker of resorption, revealed(C) Measurements of trabecular structural indices by mCT. Trabecular number (Tb.N), trabecular space (Tb.Sp), connectivity density (Conn.D), and structure
model index (SMI) are shown.
(D) Ex vivo mCT analysis of femoral cortical bone.
(E) Mechanical testing of the femur by four-point bending tests.
(F) Serum levels of osteocalcin, a marker of formation, and CTx, a marker of resorption.
All data are expressed asmean ± SEM. n = 9–11mice per group. *p < 0.05, **p < 0.01, and ***p < 0.001 compared to baseline and/or to the corresponding vehicle-
treated group. #p < 0.05 and ##p < 0.001 compared to T-cell-replete, iPTH-treated mice.etabolism 10, 229–240, September 2, 2009 ª2009 Elsevier Inc. 231
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PTH Anabolism and T-Cell-Produced Wnt10bTable 1. Effect of iPTH Treatment on Histomorphometric Indices of Trabecular and Cortical Bone Turnover inWTMice, TCRb/Mice,
and TCRb/ Mice Subjected to Adoptive Transfer of WT T Cells 1 Week before the Initiation of iPTH Treatment
WT Veh WT PTH TCRb/ Veh TCRb/ PTH TCRb/ + T Veh TCRb/ + T PTH
MAR (mm/day) 1.74 ± 0.05 2.06 ± 0.07a 1.89 ± 0.07 2.02 ± 0.08 1.75 ± 0.10 2.06 ± 0.09a
BFR/BS (mm3/mm2/day) 0.62 ± 0.06 1.36 ± 0.05c 0.59 ± 0.10 0.88 ± 0.08 0.57 ± 0.06 1.37 ± 0.10c
Ob.S (mm) 2.2 ± 0.3 12.0 ± 0.7c 2.4 ± 0.2 5.4 ± 0.5a,d 2.4 ± 0.2 12.8 ± 0.7c
Oc.S (mm) 1.0 ± 0.1 1.7 ± 0.2a 0.7 ± 0.1 1.0 ± 0.2 1.0 ± 0.1 1.8 ± 0.2a
N.Oc/BS (mm1) 3.1 ± 0.1 1.9 ± 0.3b 2.9 ± 0.3 2.5 ± 0.1 3.0 ± 0.3 1.8 ± 0.1c
Oc.S/BS (%) 10.1 ± 0.4 6.5 ± 0.9b 9.1 ± 0.7 8.0 ± 0.5 9.6 ± 0.9 6.2 ± 0.4c
Ec.MAR (mm/day) 2.15 ± 0.2 2.27 ± 0.10 2.10 ± 0.1 2.30 ± 0.20 2.27 ± 0.20 2.33 ± 0.20
Mineral apposition rate (MAR) and bone formation rate (BFR) are dynamic indices of trabecular bone formation. Ob.S (the length of bone surface occu-
pied by osteoblasts) is a static index of trabecular bone formation. Oc.S (the length of bone surface occupied by OCs), N.OC/BS (the number of oste-
oclasts per mm2 bone surface), and OcS/BS (the percentage of bone surface occupied by osteoclasts), are indices of trabecular bone resorption.
Ec.MAR is an index of endocortical bone formation. n = 9–11 mice per group. All data are expressed as mean ± SEM.
a p < 0.05 compared to the corresponding vehicle-treated group.
b p < 0.01 compared to the corresponding vehicle-treated group.
c p < 0.001 compared to the corresponding vehicle treated group.
d p < 0.05 compared to T-cell-replete iPTH-treated mice.that iPTH increased bone resorption in WT mice and in T-cell-
reconstituted TCRb/ mice, but not in T-cell-deficient mice.
Analysis of the secondary spongiosa by bone histomorphometry
confirmed that iPTH increased trabecular bone formation in
T-cell-replete mice, but not in TCRb/ mice (Table 1), as as-
sessed by measurements of mineral apposition rate (MAR) and
bone formation rate (BFR). In contrast, in all groups, iPTH failed
to cause a significant increase in endocortical MAR (Ec.MAR).
iPTH had no significant effects on indices of trabecular bone
resorption in T-cell-deficient mice, whereas it caused an
increase in total OC surface (Oc.S) in WT and T-cell-reconsti-
tuted mice. In response to iPTH, T-cell-replete mice also ex-
hibited a decrease in both the number of OCs per bone surface
(N.Oc/BS) and the percentage of surfaces covered by OCs
(Oc.S/BS), a phenomenon explained by the fact that, in control
mice, iPTH increased bone surfaces more markedly than OC
number and OC surfaces.
The finding that iPTH fails to stimulate in vivo bone resorption
in TCRb/ mice may suggest that iPTH induces T cell produc-
tion of osteoclastogenic cytokines. Because T cells secrete large
amounts of soluble RANKL (Kong et al., 1999), we measured the
production of RANKL by BM and spleen CD4+ and CD8+ T cells
harvested fromWTmice treatedwith iPTH or vehicle for 4weeks.
These studies revealed that iPTH increased the production of
RANKL by BM CD8+ cells by 2- to 3-fold, whereas it had no
effects on BM CD4+ cells (Figures S2A and S2B), suggesting
that RANKL production by BM CD8+ cells may play a role in
the stimulation of bone resorption induced by iPTH. Additional
experiments disclosed that iPTH increased by 30%–35%
the fraction of TNFa+ CD8+ cells and IFNg+ CD8+ cells
(Figure S3A), although this difference was not statistically signif-
icant. The stimulation of cytokine production by CD8+ cells
caused by PTH was associated with a nonsignificant increase
in the expression of the activation marker CD69 and a minimal
stimulation of CD25 expression (Figure S3B). iPTH had negligible
effects on the expression of both markers on CD4+ cells.
To investigate the effects of iPTH in additional strains of T-cell-
deficient mice, iPTH was injected for 4 weeks in nude mice,
a strain with a severe deficiency of ab T cells, and in Rag2/232 Cell Metabolism 10, 229–240, September 2, 2009 ª2009 Elseviemice, a strain that lacks both T andB cells. mCT analysis revealed
(Figure 2A) that iPTH caused a smaller increase in BV/TV in
Rag2/ mice and no increase in BV/TV in nude mice, as
compared to WT controls. Measurements of serum osteocalcin
showed that iPTH failed to stimulate bone formation in both
nude andRag2/mice, whereas it caused a significant increase
in osteocalcin levels in WT mice. Together, these findings not
only confirm that T cells potentiate the anabolic activity of iPTH
by stimulating bone formation, but also suggest that, although
T cells play an amplificatory role in some strains, in others, the
presence of T cells is an essential requirement for iPTH-medi-
ated trabecular bone anabolism.
To characterize the subset of T cells required for iPTH to
promote bone anabolism, we injected iPTH in class II MHC/
(Abb/) mice that lack CD4 T cells, class I MHC/ (b2 m/)
mice that lack CD8 T cells, and double MHC/ mice that lack
both populations. iPTHmarkedly increased BV/TV and osteocal-
cin in WT mice, caused a slightly blunted response in class II
MHC/ mice, and induced no changes in class I MHC/ and
double MHC/ mice (Figure 2B). These findings suggest that
iPTH promotes bone anabolism mostly through CD8+ T cells,
and CD4+ cells play a small contributory role.
The pivotal role of CD8+ cells was confirmed by adoptively
transferring CD4+ or CD8+ cells into TCRb/ mice. Measure-
ments of BV/TV by mCT revealed (Figure 2C) that iPTH increased
BV/TV in WT mice and TCRb/ animals reconstituted with
CD8+ T cells, whereas it had no effects in T-cell-deficient
mice, TCRb/ mice, and TCRb/ animals reconstituted with
CD4+ T cells.
T-Cell-Deficient Mice Exhibit a Blunted
Osteoblastogenic Response to iPTH
BM from WT, TCRb/, and T-cell-reconstituted TCRb/ mice
treated with iPTH was utilized to assess the formation of alkaline
phosphatase (ALP)-positive colony-forming unit fibroblast (CFU-
F), herein defined CFU-ALP, an index of SC commitment to the
osteoblastic lineage. iPTH treatment increased by 2-fold the
CFU-ALP formation in the BM of T-cell-replete mice, whereas
it had no effect in that of TCRb/ mice (Figure 3A), thusr Inc.
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PTH Anabolism and T-Cell-Produced Wnt10bindicating that T cells potentiate the capacity of iPTH to increase
the number of SCs with osteogenic potential.
To directly evaluate the role of T cells in iPTH-induced osteo-
blastogenesis, we cultured BM from iPTH-treated T-cell-replete
and TCRb/ mice for 1 week to allow SCs to proliferate and
differentiate into pre-OBs. Pre-OBs were then purified and
counted. This analysis revealed (Figure 3B) that in vivo iPTH treat-
ment increases the number of pre-OBsby50% in samples from
WTandT-cell-reconstituted TCRb/mice. In contrast, iPTHhad
no effects on the number of pre-OBs from TCRb/ mice. To
investigate the mechanism involved, BM was cultured for 1
week, and pre-OBs were purified and used to determine their
rate of proliferation and apoptosis. These experiments revealed
that iPTH increases significantly the proliferation of WT and
T-cell-reconstituted TCRb/ mice pre-OBs, but not those from
TCRb/ mice (Figure 3C). Moreover, iPTH decreased the rate
ofpre-OBapoptosis in all groupsofmice.However, theantiapop-
totic effect of iPTH was smaller in pre-OBs from TCRb/ mice
than in those fromWT and T-cell-reconstituted TCRb/ controls
(Figure 3D). Analysis of the expression levels of osteoblastic
genes in pre-OBs revealed that iPTH increases the expression
of type 1 collagen mRNA by 5-fold and that of Runx2, Osterix,
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Figure 2. Analysis of the Effects of iPTH
Treatment in Additional Strains of T-Cell-
Deficient Mice
(A) Trabecular BV/TV and serum osteocalcin levels
in nude and RAG2/ mice. n = 11–13 mice per
group.
(B) Trabecular BV/TV and serum osteocalcin levels
in class IIMHC/mice that lack CD4 T cells, class
I MHC/ mice that lack CD8 T cells, and double
MHC/ mice that lack both populations. n = 6–8
mice per group.
(C) Trabecular BV/TV in TCRb/ mice subjected
to adoptive transfer of either CD4+ or CD8+
T cells 1 week before initiation of iPTH. n = 5–10
mice per group.
All data are expressed as mean ± SEM. ***p <
0.001 compared to the corresponding vehicle
treated group. *p < 0.05, **p < 0.01, ***p < 0.001
compared to the corresponding vehicle-treated
group. #p < 0.05 and ###p < 0.001 compared to
the indicated groups.
Bone Sialoprotein, and Osteocalcin
mRNAs by 2-fold in pre-OBs from WT
mice and T-cell-reconstituted TCRb/
mice (Figure 3E). In contrast, iPTH had
no effects on the expression of OB-
related genes in cells from TCRb/
mice, thus demonstrating that T cells
promote the capacity of iPTH to expand
the osteoblastic pool and cell differentia-
tion along the osteoblastic lineage.
TCellsRegulateOsteoblastogenesis
throughWnt10b
To determine whether T cells are required
for iPTH to activate Wnt signaling in
osteoblastic cells, we cultured BM from
iPTH-treated WT and TCRb/ mice for 1 week and purified
pre-OBs. Pre-OB expression of mRNA for genes known to be
upregulated by Wnt signaling was then assessed by real-time
RT-PCR. The analyzed genes were chosen based on known
expression patterns during differentiation of primitive mesen-
chymal cells to the osteoblast phenotype. Some of the selected
genes are known to play a direct role in regulating OB differenti-
ation (Vaes et al., 2005), whereas others are not involved in
OB differentiation but are sensitive markers of Wnt activation
(Jackson et al., 2005). These analyses revealed (Figure 4A) that
iPTH activates Wnt signaling in pre-OBs through T cells, as
pre-OB levels of mRNA for 9 of the 12 tested genes were all
increased by iPTH in pre-OBs from WT, but not in those from
T-cell-deficient TCRb/ mice, whereas the mRNA levels of the
remaining three genes were not increased by iPTH in both WT
and TCRb/ mice. The nine genes that were stimulated by
iPTH were: aryl-hydrocarbon receptor (Ahr), axin2, cysteine-
rich protein 61 (Cyr61), naked cuticle 2 homolog (Nkd2), transge-
lin (tagln), transforming growth factor b3 (TGFb3), thrombospon-
din 1 (Thbs1), twist gene homolog 1 (Twst1), and Wnt1-inducible
signaling pathway protein 1 (Wisp1). The three genes that were
not stimulated by iPTH were: cyclin D1 (Ccnd1), insulin-likeCell Metabolism 10, 229–240, September 2, 2009 ª2009 Elsevier Inc. 233
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Figure 3. Analysis of the Effects of iPTH Treatment on Osteoblastogenesis and Pre-OB Apoptosis in WT, TCRb/Mice, and TCRb/Mice
Previously Subjected to Adoptive Transfer of WT T Cells
(A) Whole BM was cultured for 7 days to assess the formation CFU-ALP. (Left) Representative duplicate wells per group. (Right) The average of the colonies
counted in 6 wells.
(B) BM harvested at sacrifice was cultured for 1 week, and pre-OBs were purified and counted.
(C) Pre-OBs were purified from BM cultured for 1 week, seeded in equal number, and pulsed with [3H]-thymidine for 18 hr to assess their proliferation. Data are
expressed in CPM.
(D) Pre-OBs were purified from BM cultured for 1 week, and the rate of apoptosis was quantified by determinations of caspase 3 activity.
(E) Pre-OBs were purified from BM cultured for 1 week, and the levels of OB marker gene mRNAs, bone sialoprotein (BSP), type I collagen (Col1a1), osteocalcin
(Ocn), osterix (Osx), and runt-related transcription factor 2 (Runx2) were analyzed by RT-PCR.
All data are expressed asmean ± SEM. n = 4–5 per group. *p < 0.05, **p < 0.01, and ***p < 0.001 compared to the corresponding vehicle-treated group. #p < 0.001
compared to the indicated group.growth factor binding protein 2 (Igfbp2), and osteomodulin
(Omd).
Having established that T cells are required for iPTH to activate
Wnt signaling in OBs, we sought to identify the ligands involved.
Wnt10b is a candidate factor produced by mesenchymal stem
cells and T lymphocytes (Hardiman et al., 1996; Ouji et al.,
2006), which promotes OB differentiation and increases bone
density (Bennett et al., 2005). To determine whether iPTH
increases Wnt10b expression and the responsible cell lineages,
BMwas harvested fromWT and TCRb/mice treatedwith iPTH
or vehicle for 4 weeks and assayed for Wnt10bmRNA levels. BM
fromWT mice was also utilized to purify pre-OBs, dendritic cells234 Cell Metabolism 10, 229–240, September 2, 2009 ª2009 Elsevie(DCs), T cells, monocytes, and B cells. Analysis by real-time RT-
PCR disclosed that iPTH increases the whole BM expression of
Wnt10b mRNA by 2-fold in WT mice, but not in TCRb/ mice.
Among individual lineages of WT BM, T lymphocytes were the
only cells that responded to iPTH with a significant increase
(5-fold) in Wnt10b expression (Figure 4B).
To characterize the PTH-responsive T cell subset, CD4+ and
CD8+ cells were purified from the spleen and the BM of iPTH-
treated WT mice and analyzed by real-time RT-PCR. These
studies disclosed that iPTH treatment increases the levels of
Wnt10b mRNA in BM CD4+ and CD8+ T cells by 4-fold and
13-fold, respectively (Figure 4C). In contrast, iPTH had nor Inc.
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T cells. Analysis of Wnt7a and Wnt3a, two ligands that also
promote bone anabolism, disclosed that iPTH caused a 4-
fold increase in CD4+ cell production of Wnt7b mRNA but failed
to alter the mRNA levels of Wnt3a in all populations of T cells.
Further analysis by western blotting confirmed that iPTH upregu-
lates the production of Wnt10b by BMCD8+ T cells by4.5-fold
(Figure 4D). In contrast, Wnt7b protein was not detected in
spleen and BM CD4+ and CD8+ T cells (Figure S4A), indicating
that T-cell-produced Wnt7b does not contribute to activate
Wnt signaling in OBs.
To determine whether T-cell-produced Wnt10b has the
capacity to activate canonical Wnt signaling in OBs, CD4+ and
CD8+ T cells purified from the BM of iPTH-treated WT mice
were cocultured with the osteoblastic cell line MC3T3-E1 and
transiently transfected with the b-catenin/TCF-luciferase re-
porter plasmid TOPFLASH or with the negative control plasmid
FOPFLASH (Almeida et al., 2005). Analysis of luciferase activity
in transfected MC3T3-E1 cells revealed that, whereas the addi-
tion of CD8+ T cells from iPTH-treated mice activates TCF-
mediated transcription, the addition of CD4+ T cells does not
(Figure 4E). Together, these findings demonstrate that iPTH up-
regulates the CD8+ T cell production of Wnt10b and that T-cell-
produced Wnt10b activates canonical Wnt signaling in osteo-
blastic cells.
WT and Wnt10b/ donor mice were similar with respect to
CD4+/CD8+ ratio (Figure S5A) and numbers of naive and
memory BM T cells (Figure S5B). Furthermore, WT and
Wnt10b/ T cells exhibit similar rates of proliferation (Fig-
ure S5C) and expression of activation markers in response to
T cell receptor crosslinking (Figure S5D). However, mice lacking
Wnt10b/ have a markedly decreased bone volume and bone
formation (Bennett et al., 2005), a phenotype that prevents es-
tablishing the role of Wnt10b in PTH-induced bone anabolism
by comparing the response of WT and Wnt10b/ mice to
iPTH. Therefore, to demonstrate the specific relevance of
T-cell-produced Wnt10b in vivo, equal numbers of splenic
T cells fromWT andWnt10b/micewere adoptively transferred
into 6-week-old TCRb/mice. After 1 week, reconstituted mice
were treated with vehicle or iPTH for 4 weeks. FACS analysis of
splenocytes harvested at sacrifice frommice subjected to adop-
tive transfer of T cells revealed that mice reconstituted with WT
T cells and Wnt10b/ T cells had similar numbers of CD4+
and CD8+ cells (Figure S6).
Measurements of femoral BV/TV by mCT and of serum indices
of turnover at 4 weeks revealed (Figure 4G) that iPTH increased
BV/TV and osteocalcin in WT mice and in TCRb/ animals re-
constituted with WT T cells, whereas it had no effects in both
T-cell-deficient mice and TCRb/ mice reconstituted with
Wnt10b/ T cells. In contrast, iPTH failed to augment CTx levels
in T-cell-deficient mice but increased CTx levels in TCRb/
mice reconstituted with WT orWnt10b/ T cells. These findings
demonstrate that iPTH stimulates bone formation and promotes
bone anabolism through T-cell-produced Wnt10b.
In Vitro PTH Treatment Stimulates T Cell Wnt10b
Production
To investigate whether T cells have the capacity to directly
respond to PTH, 99% pure splenic CD4+ and CD8+ T cellsCell Mwere prepared from untreated WT mice by immunomagnetic
cell sorting (Figure S7). The PTH receptor PPR was found to be
expressed in both CD4+ and CD8+ cells, although the levels of
the receptor were higher in CD8+ cells (Figure 5A). Stimulation
of T cells by PTH induced a significant increase in the production
of cAMP in both CD4+ and CD8+ cells within 10 min (Figure 5B),
demonstrating that both T cell lineages are responsive to PTH.
In vitro treatment with PTH for 3 hr increased the expression of
Wnt10b mRNA by nonactivated CD8+ T cells cultured with and
without the phosphodiesterase inhibitor 3-isobutyl-1-methyl-
xanthine (IBMX) (Figure 5C), although the stimulatory effect of
PTH was significantly higher in IBMX pretreated cells. PTH did
not induce a higher expression of Wnt10b in activated CD8+
cells, indicating that T cell activation is not required for PTH
induction of Wnt10b production. Pretreatment with H89,
a specific PKA inhibitor, abolished PTH increase in Wnt10b
mRNA expression in resting CD8+ T cells (Figure 5D), suggesting
that PTH increases Wnt10b mRNA expression primarily through
the Gs/cAMP/PKA pathway. PTH also increased Wnt10b mRNA
production by IBMX-treated human CD8+ T cells (Figure 5E),
though it did not alter Wnt10b mRNA levels in murine pre OBs
(Figure 5F). These findings demonstrate that PTH has the
capacity to directly stimulate T cell production ofWnt10b in vitro.
DISCUSSION
We report that iPTH markedly increases the production of
Wnt10b by bone marrow CD8+ T cells and that the activation
of Wnt signaling in osteoblastic cells by T-cell-produced
Wnt10b plays a relevant role in the mechanism by which iPTH
increases bone strength. This insight supports a role for immune
cell-bone cell crosstalk in the mechanism of action of PTH.
T cells were found to augment the capacity of iPTH to improve
architecture in trabecular, but not in cortical, bone. Although the
reason of this selectivity is unknown, a lack of access of T cells to
cortical surfaces is not a likely explanation, as T cells reach
endosteal and periosteal bone surface through blood vessels
and recirculate in and out of the BM (Di Rosa, 2008).
The relevance of T cells in vivo was demonstrated in TCRb/
mice and confirmed in additional T-cell-deficient strains
RAG2/, nude, and MHC/ mice. Our findings extend earlier
observations by Pettway et al., who reported that daily injections
of PTH for up to 7 weeks did not induce vertebral bone growth in
nude mice (Pettway et al., 2005). InMHC/ and nude mice, the
anabolic activity of iPTH was completely absent, whereas in the
others, it was markedly, but not completely, silenced. Moreover,
in TCRb/mice, the anabolic activity of iPTH was more attenu-
ated in animals treated from 7 to 11 weeks of age than in those
started on iPTH at 5 weeks.
Osteoblastic cells produce several bone anabolic Wnt ligands,
including Wnt10b, Wnt7a, and Wnt3b (Luo et al., 2004; Rawadi
et al., 2003). These factors are likely to contribute to the T-cell-
independent anabolic activity of iPTH, and quantitative differ-
ences in their production may account, in part, to the strain
and age-dependent variability in the response to iPTH observed
herein. Furthermore, the magnitude of the anabolic response to
iPTH in T cell null mice may be related to a strain- and age-
dependent capacity of iPTH to inhibit the bone cells’ production
of Wnt inhibitors such as sclerostin (Bellido et al., 2005; Kelleretabolism 10, 229–240, September 2, 2009 ª2009 Elsevier Inc. 235
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Figure 4. Analysis of the Role of Wnt10b and Wnt Signaling in iPTH-Induced Anabolism
(A) Effect (mean ± SEM) of iPTH on the expression of mRNA of genes known to be upregulated byWnt signaling, aryl-hydrocarbon receptor (Ahr), axin2, cysteine-
rich protein 61 (Cyr61), naked cuticle 2 homolog (Nkd2), transgelin (tagln), transforming growth factor b 3 (TGFb3), thrombospondin 1 (Thbs1), twist gene homolog
1 (Twst1), and Wnt1-inducible signaling pathway protein 1 (Wisp1). BM was harvested at sacrifice from WT and TCRb/ treated with vehicle of iPTH. BM was
cultured for 1 week, pre-OBs were purified, and mRNA levels were determined by RT-PCR. n = 4 mice per group.
(B) Effect (mean ± SEM) of iPTH on the expression of Wnt10b mRNA in whole BM and BM T cells, dendritic cells, monocytes, B cells, and pre-OBs purified from
BM samples obtained at sacrifice. Data are expressed relative to pre-OBs from vehicle treated mice. n = 10 mice per group.236 Cell Metabolism 10, 229–240, September 2, 2009 ª2009 Elsevier Inc.
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Figure 5. Analysis of the Effects of In Vitro
PTH Treatment in T Cells
(A) Measurement of PPR expression by western
blotting in spleen CD4+ and CD8+ T cells from
intact mice. PPR-negative LLCPK-1 cells stably
transfected with empty vector (LLCPK-1 PPR)
or PPR expression vector (LLCPK-1 PPR+) are
negative and positive controls, respectively.
CD4+, CD8+, LLCPK-1 PPR, and LLCPK-1
PPR+ lanes were run in the same gel but were
noncontiguous.
(B) Effect (mean ± SEM) of in vitro PTH treatment
(50 nM) on the production of cAMP by spleen
CD4+ and CD8+ T cells from intact mice. Forskolin
was used as a positive control. *p < 0.05 and ***p <
0.001 as compared to the corresponding vehicle.
(C) Effect (mean ± SEM) of in vitro PTH treatment
on the expression of Wnt10b mRNA by murine
CD8+ T cells. Splenic CD8+ T cells were purified,
stimulated with or without plate-bound anti-CD3
plus anti-CD28 mAbs for 24 hr, and cultured with
PTH (50 nM) for 3 hr. The phosphodiesterase
inhibitor IBMX (100 mM) or vehicle was added in
the indicated samples 1 hr before PTH. *p < 0.05
and ***p < 0.001 compared to mAbs, IBMX,
PTH samples. #p < 0.05 compared to the other
groups.
(D) Effect (mean ± SEM) of the PKA inhibitor H89
on the PTH-induced production of Wnt10b by un-
stimulated splenic CD8+ T cells. Purified cells
were cultured with PTH (50 nM) and H89 (25 mM)
for 3 hr. *p < 0.05 compared to the other groups.
(E) Effect (mean ± SEM) of in vitro PTH treatment
on the expression of Wnt10b mRNA by ex vivo
expanded human CD8+ T cells. Data are from
one of three representative experiments. *p <
0.05 compared to vehicle.
(F) Effect (mean ± SEM) of in vitro PTH treatment
on the osteoblastic expression of Wnt10b. Pre-
OBs were purified from the BM of untreated WT
mice and were cultured with PTH 50 nM for 3 hr.and Kneissel, 2005), Dickkopf-1 (Kulkarni et al., 2005), and Sfrp-
4 (Qin et al., 2003). These factors have been shown to contribute
to the anabolic activity of iPTH through T-cell-independent
mechanisms. Because B cells are regulated by PTH (Alexiewicz
et al., 1990), the response of RAG2/ mice to iPTH might also
have been determined by the lack of B cells, which is a feature
of RAG2/ mice.
The enhancement of bone formation induced by iPTH is
accompanied by a stimulation of bone resorption, which is driven
by increased production of RANKL and decreased release of
OPG in the bone microenvironment (Ma et al., 2001). The directCell Meffects of PTH on RANKL/OPG production are mitigated, in part,
by the iPTH-induced activation of b catenin in OBs, as this tran-
scriptional regulator stimulates their production of OPG (Glass
et al., 2005) and represses that of RANKL (Spencer et al.,
2006). The latter is one of the mechanisms that prevent bone
resorption from offsetting the anabolic activity of iPTH. Accord-
ingly, we found that iPTH increased CTx levels and total OC
surfaces in T-cell-replete mice. In agreement with studies by
others (Iida-Klein et al., 2002), the stimulation of bone resorption
induced by iPTH was not reflected by measurements of the
number of OCs and OC surfaces per unit of trabecular bone(C) Effect (mean ± SEM) of iPTH on the expression of Wnt3a, Wnt7b, and Wnt10b mRNA in spleen and BM CD4+ and CD8+ T cells purified from samples har-
vested at sacrifice. n = 10 mice per group.
(D) Measurement of Wnt10b protein levels by western blotting in spleen and BMCD4+ and CD8+ T cells purified from samples harvested at sacrifice. The bottom
panel shows the densitometric quantification of the data shown in the top panel. n = 10 mice per group.
(E) Effect (mean ± SEM) of T cells from iPTH-treated mice on Wnt signaling in the MC3T3-E1 osteoblastic cell line. MC3T3-E1 cells were transiently transfected
with the TCF-luciferase reporter (TOPFLASH) or a control vector lacking the TCF-binding site (FOPFLASH) and were cocultured with either CD4+ or CD8+ T cells
derived from the BM of WT mice treated with iPTH. Data are expressed as the mean of triplicate determinations of luciferase activity normalized for pRL-TK
activity. n = 4 mice per group.
(F) Analysis of the effects (mean ± SEM) of iPTH treatment inWTmice, TCRb/mice, and TCRb/mice subjected to adoptive transfer of T cells derived fromWT
mice andWnt10b/mice 1 week before initiation of iPTH. The panels show trabecular BV/TV asmeasured by mCT at sacrifice and serum osteocalcin and CTx at
4 weeks. n = 8 mice per group. *p < 0.05, **p < 0.01, and *** = p < 0.001 compared to the corresponding vehicle-treated group.etabolism 10, 229–240, September 2, 2009 ª2009 Elsevier Inc. 237
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increased bone surfaces more markedly than OC number and
OC surfaces. As a result, the percentages of OC surfaces were
observed to be slightly decreased. By contrast, neither CTx
nor histomorphometric indices of bone resorption was signifi-
cantly affected by iPTH in T-cell-deficient mice. In a previous
study, continuous PTH treatment was similarly found unable to
stimulate bone resorption in T-cell-depleted mice (Gao et al.,
2008). The capacity of iPTH to elicit a resorptive response in
T-cell-replete mice, but not in T-cell-deficient animals, may be
explained, in part, by the increased production of RANKL by BM
CD8+ T cells induced by iPTH. Another likely contributory mech-
anism is the capacity of T cells to lead to the generation of BM
SCs, which respond to PTH by producing higher levels of RANKL
and lower levels of OPG, as compared to the SCs that differen-
tiate in the BM of T-cell-deficient mice (Gao et al., 2008).
We show herein that osteoblastic cells from WT mice treated
with iPTH in vivo exhibited increased commitment to the osteo-
blastic lineage, proliferation, differentiation, and life span in vitro,
as compared to the corresponding cells from T-cell-deficient
mice. Thus, T cells, like PTH, affect all aspects of OB life cycle.
Remarkably, these differences were demonstrated in OBs puri-
fied from BM cultured for 7 days without the addition of PTH,
suggesting that, in vivo, the hormone regulates early commit-
ment steps of SCs and their osteoblastic progeny through
T-cell-produced Wnt10b and that these steps are not reversed
by the absence of PTH and T cells in vitro. This model is consis-
tent with the capacity of Wnt signaling to guide cell fate determi-
nation (Moon et al., 2002). A similar paradigm has been de-
scribed in ovariectomized mice, a model in which estrogen
withdrawal in vivo leads to the formation of SCs, which exhibit
an increased osteoclastogenic activity that persists in vitro for
4 weeks (Kimble et al., 1996).
Activation of the Wnt-signaling pathway in cells of the osteo-
blastic lineage plays a relevant role in iPTH-induced anabolism
(Bodine and Komm, 2006; Kulkarni et al., 2005), but the specific
signaling molecules involved remains uncertain. LRP5 is now
recognized to stimulate bone formation by inhibiting serotonin
synthesis in the duodenum, rather than functioning as aWnt cor-
eceptor in OBs (Yadav et al., 2008). Accordingly, LRP5/ mice
are fully responsive to iPTH (Iwaniec et al., 2007; Sawakami et al.,
2006). iPTH may promote Wnt signaling by activating the closely
related receptor LRP6, which is also expressed in cells of the
osteoblastic lineage (Jilka, 2007). Alternatively, iPTH could acti-
vate noncanonical Wnt-signaling pathways that are independent
of LRP5 and LRP6. Our data show that T cells activate canonical
Wnt signaling in pre-OBs. However, we have not determined
whether T cells activate LRP5 or LRP6 signaling in pre-OBs
nor the effects of T cells on noncanonical Wnt signaling.
The specificWnt ligands responsible for the iPTH-induced acti-
vation of Wnt signaling are also unknown. We found that iPTH
markedly upregulates the production of Wnt10b by BM CD8+
T cells and that the capacity of activatingWnt signaling in an oste-
oblastic line is a feature of CD8+ T cells. The relevance of CD8+
cells was demonstrated by the inability of iPTH to promote bone
anabolism in class I MHC/ mice, and the pivotal role of T-cell-
produced Wnt10b was revealed by the hampered effect of iPTH
on BV/TV and bone turnover in TCRb/mice reconstituted with
T cells fromWnt10b/ mice. iPTH also caused a small increase238 Cell Metabolism 10, 229–240, September 2, 2009 ª2009 Elseviein the production of Wnt10b by BM CD4+ cells, which was asso-
ciated with a slightly diminished anabolic response in class II
MHC/ mice, suggesting that production of Wnt10b by CD4+
cells contributes, in small part, to the anabolic activity of iPTH.
It is likely that iPTH directly targets CD8+ T cells and stimulates
their production of Wnt10b. This hypothesis is supported by the
strong expression of PPR in CD8+ T cells and the capacity of
in vitro PTH treatment to promote cAMP production and
Wnt10b expression in CD8+ murine and human lymphocytes.
However, we cannot conclusively exclude that in vivo iPTH treat-
ment might induce CD8+ T cell production of Wnt10b indirectly.
Whereas in vitro PTH treatment increased Wnt10b mRNA
expression in splenic T cells, iPTH upregulated Wnt10b produc-
tion only by BM T cells. This diversity might be explained by the
different dose and time of exposure to PTH. However, because
adoptive transfer of spleen T cells into TCRb/ mice was fol-
lowed by a restoration of a full responsiveness to iPTH, the
data suggest that the capacity of T cells to upregulate their
production of Wnt10b in response to iPTH is not an intrinsic
feature of T cells, but rather is induced by environmental cues.
In summary, this study indicates that T cells represent a regu-
latory component of the BM microenvironment involved in the
anabolic response to iPTH. Bone anabolism is induced by PPR
signaling in SCs and their osteoblastic progeny, but T cells
play a permissive role by producing Wnt10b in response to stim-
ulation by iPTH. Understanding the crosstalk between T cells
and osteoblastic cells may thus yield novel therapeutic strate-
gies for potentiating bone anabolic agents.
EXPERIMENTAL PROCEDURES
Animals
The animal procedures were approved by the Institutional Animal Care and
Use Committee of Emory University. Additional information is provided in
the Supplemental Data.
Intermittent Administration of PTH
Human PTH (1–34) (Bachem California, Inc., Torrance, CA) or vehicle were in-
jected at doses of 80 mg/kg/day subcutaneously for 4 weeks in 5- to 6-week-
old mice.
Purification of T and B Cells, Monocytes, and Dendritic Cells
and T Cell Transfer
Information is provided in the Supplemental Data.
Flow Cytometry
Splenocytes and BM cells were stained with APC anti-mouse CD4 (BioLe-
gend, San Diego, CA), PerCP anti-mouse CD8, FITC anti-mouse MHCII, PE
anti-mouse CD20, PE anti-mouse Cd11b, PE anti-mouse CD69, and FITC
anti-mouse CD25 (BD Biosciences, San Jose, CA) mAbs and propidium Iodide
solution. Samples were analyzed by flow cytometry on a FACSort flow cytom-
eter (BD Biosciences).
In Vivo BMD Measurements
Total body and femoral BMD were measured in anesthetized mice using
a PIXImus2 bone densitometer (GE Medical System, Lunar, Madison, WI) as
described (Cenci et al., 2003).
mCT Measurements
mCT scanning and analysis was performed as reported previously (Gao et al.,
2007), using a Scanco mCT-40 scanner (Scanco Medical, Bassersdorf,
Switzerland). Cortical bone volume and cortical thickness were determined
by analyzing 80 slices at the middiaphysis of the femurs.r Inc.
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PTH Anabolism and T-Cell-Produced Wnt10bBone Histology and Quantitative Bone Histomorphometry
Histology of the distal metaphysis of the left femora was performed by the His-
tomorphometry and Molecular Analysis Core Laboratory of the Center for
Metabolic Bone Disease, University of Alabama at Birmingham as described
(Gao et al., 2008). Additional information is provided in the Supplemental Data.
Mechanical Testing
The mechanical properties of the right femora were analyzed via four-point
bending as described elsewhere (Robertson et al., 2006). Each femur was
tested to failure at a displacement rate of 0.05 mm/s, with the supports
centered on the middiaphysis and the anterior side of the bone in tension.
The resultant force displacement curves were analyzed to obtain force and
deflection data.
Markers of Bone Turnover
Serum osteocalcin was measured using Rat-MID Osteocalcin ELISA kit
(Immunodiagnostic Systems Inc., Fountain Hills, AZ). Serum CTx was
measured using the RatLaps ELISA kit (Immunodiagnostic Systems Inc.,
Fountain Hills, AZ).
CFU-ALP Assay
Colony-forming assays were carried out as described (Gao et al., 2008). Real-
time RT-PCR, thymidine incorporation assay, apoptosis assay, luciferase
assay, cAMP assay, western blots, and statistical analysis information are
provided in the Supplemental Data.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and eight
figures and can be found with this article online at http://www.cell.com/
cell-metabolism/supplemental/S1550-4131(09)00228-9.
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